The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20+
SponsorNational Health Research Institutes, Taiwan
About this trial
We will use the next-generation sequencing (NGS) technology to identify genomic alterations of Taiwanese HPV positive and negative oropharyngeal squamous cell carcinoma (OPSCC) for novel biomarker development and the study design of potential clinical trials or translational research.
Eligibility criteria
Qualifiers
Ages 20 and above
Pathological reported as squamous cell carcinoma of head and neck
Available p16 immunohistochemical staining status (restricted to the OPSCC subgroup)
Participants have both archival tumor tissues from the primary head and neck SCC and from the first recurrent tumor (for the recurrence subgroup)
Disqualifiers
Inability to cooperate by providing a complete medical history
No available tumor tissues for genetic testing
Undesirable compliance
Having a known additional malignancy that is progressing or has required active treatment within the past 3 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g., cervical carcinoma in situ) that have undergone potentially curative therapy are not excluded
Trial design
Treatments tested in this trial
- Not listed
Trial groups
410 Participants
are grouped into 6 trial groups6
Trial groupsSee each trial group below.
Sponsors and collaborators
National Health Research Institutes, Taiwan
Lead sponsor
National Taiwan University Hospital
Collaborator
Taipei Veterans General Hospital, Taiwan
Collaborator
China Medical University Hospital
Collaborator
Taichung Veterans General Hospital
Collaborator
National Cheng-Kung University Hospital
Collaborator
Kaohsiung Veterans General Hospital.
Collaborator
Kaohsiung Medical University Chung-Ho Memorial Hospital
Collaborator
Source ClinicalTrials.gov